280 related articles for article (PubMed ID: 24281081)
1. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.
Tomasetti M; Santarelli L
Cancers (Basel); 2010 Apr; 2(2):523-48. PubMed ID: 24281081
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Ciuccarelli M; Valentino M; Governa M; Santarelli L
G Ital Med Lav Ergon; 2007; 29(3 Suppl):335-8. PubMed ID: 18409713
[TBL] [Abstract][Full Text] [Related]
3. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
[TBL] [Abstract][Full Text] [Related]
4. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma.
Santarelli L; Strafella E; Staffolani S; Amati M; Emanuelli M; Sartini D; Pozzi V; Carbonari D; Bracci M; Pignotti E; Mazzanti P; Sabbatini A; Ranaldi R; Gasparini S; Neuzil J; Tomasetti M
PLoS One; 2011 Apr; 6(4):e18232. PubMed ID: 21483773
[TBL] [Abstract][Full Text] [Related]
5. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
Birnie KA; Prêle CM; Thompson PJ; Badrian B; Mutsaers SE
Oncotarget; 2017 Sep; 8(44):78193-78207. PubMed ID: 29100460
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on.
Ledda C; Senia P; Rapisarda V
Cancers (Basel); 2018 Jun; 10(6):. PubMed ID: 29914087
[TBL] [Abstract][Full Text] [Related]
7. Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study.
Weber DG; Johnen G; Bryk O; Jöckel KH; Brüning T
PLoS One; 2012; 7(1):e30221. PubMed ID: 22253921
[TBL] [Abstract][Full Text] [Related]
8. [microRNAs as biological indicators of environmental and occupational exposure to asbestos].
Minoia C; Sturchio E; Porro B; Ficociello B; Zambelli A; Imbriani M
G Ital Med Lav Ergon; 2011; 33(4):420-34. PubMed ID: 22452101
[TBL] [Abstract][Full Text] [Related]
9. ATG5 as biomarker for early detection of malignant mesothelioma.
Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L
BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers in malignant mesothelioma: state of the art.
Kao SC; Reid G; van Zandwijk N; Henderson DW; Klebe S
Pathology; 2011 Apr; 43(3):201-12. PubMed ID: 21436629
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.
Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD
Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins.
Giusti L; Da Valle Y; Bonotti A; Donadio E; Ciregia F; Ventroni T; Foddis R; Giannaccini G; Guglielmi G; Cristaudo A; Lucacchini A
Proteomics Clin Appl; 2014 Apr; 8(3-4):258-68. PubMed ID: 24415579
[TBL] [Abstract][Full Text] [Related]
14. Biological agents involved in malignant mesothelioma: relevance as biomarkers or therapeutic targets.
Crispi S; Cardillo I; Spugnini EP; Citro G; Menegozzo S; Baldi A
Curr Cancer Drug Targets; 2010 Feb; 10(1):19-26. PubMed ID: 20088796
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin-family proteins and diagnosis of mesothelioma.
Robinson BW; Creaney J; Lake R; Nowak A; Musk AW; de Klerk N; Winzell P; Hellstrom KE; Hellstrom I
Lancet; 2003 Nov; 362(9396):1612-6. PubMed ID: 14630441
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
17. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
[TBL] [Abstract][Full Text] [Related]
18. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
19. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
20. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
